Profil
Andre Koltermann is Chief Executive Officer of DIREVO Biotech AG.
He has been General Partner of TVM Capital GmbH since January 1, 2001.
He is Chairman of Argos Therapeutics, Inc. and Spepharm Holding BV.
He is a Director of Evotec AG, Jerini AG, Proteon Therapeutics, Inc., and BioXell SA. Dr. Koltermann holds a PhD.
Anciens postes connus de Andre Koltermann
| Sociétés | Poste | Fin |
|---|---|---|
DIREVO Biotech AG
 DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany. | Fondateur | 22/09/2009 |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | Directeur/Membre du Conseil | - |
| PROTARA THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | - |
SpePharm Holding BV
 SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries. | Président | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
DIREVO Biotech AG
DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany. | Commercial Services |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
SpePharm Holding BV
SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries. | Health Technology |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Proteon Therapeutics, Inc.
 Proteon Therapeutics, Inc. BiotechnologyHealth Technology Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA. | Health Technology |
BioXell SpA
BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | Health Technology |